Peripheral Vascular Disease (PVD) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Closing the Racial Disparity in PAD Care
(MedPage Today) -- African Americans fare worse with peripheral artery disease (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 19, 2018 Category: Primary Care Source Type: news
Amputation Not Best Option for Circulation Woes?
Critical limb ischemia is the most severe form of peripheral artery disease (PAD) and can lead to ulcers, gangrene and amputation, the researchers said. (Source: WebMD Health)
Source: WebMD Health - August 15, 2018 Category: Consumer Health News Source Type: news
Medtronic launches In.Pact Admiral drug-coated balloon in Japan
Medtech titan Medtronic (NYSE:MDT) said today that it launched its In.Pact Admiral drug-coated balloon in Japan.
The company won approval and reimbursement for its device last year from the Japanese Ministry of Health, Labor and Welfare for the treatment of peripheral artery disease in the upper leg.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic launches In.Pact Admiral drug-coated balloon in Japan appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Vascular Wall Street Beat Medtronic Source Type: news
NuCryo Vascular inks PolarCath distro deal with Lokai Medical
Privately held cryoplasty developer NuCryo Vascular said today it inked a deal with Lokai Medical to distribute its PolarCath balloon dilation system in the US.
San Jose, Calif.-based NuCryo Vascular’s PolarCath system is designed to be used in Balloon Cryoplasty procedures to treat peripheral artery disease. The system has FDA approval and is cleared to dilate stenosis in the peripheral vasculature and for treating obstructive lesions of polytetrafluorethylene access grafts or arteriovenous dialysis fistulae, the company said
The PolarCath, which won clearance initially in 2002, was purchased along with the company ...
Source: Mass Device - August 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Catheters Distribution Vascular Boston Scientific NuCryo Vascular Source Type: news
Cardiovascular Systems touts 2-year Liberty 360 PAD study data
Cardiovascular Systems (NSDQ:CSII) yesterday released two-year results from the Liberty 360 study examining long-term clinical and economic outcomes for peripheral vascular interventions in treating patients with peripheral artery disease.
Results from the trial were presented by Dr. Jihad Mustapha of Grand Rapids, Mich.’s Advanced Cardiac & Vascular Amputation Prevention Centers in a late-breaking presentation at the 2018 Amputation Prevention Symposium in Chicago.
In the 1,204-patient “all comers” study, investigators examined effects of treatment with a number of different FDA-cleared devices for ...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Cardiovascular Systems Inc. Source Type: news
AHA: Obesity May Increase Risk for Peripheral Artery Disease
THURSDAY, Aug. 9, 2018 (American Heart Association) -- People with obesity are known to be at increased risk for coronary heart disease, the most common type of heart disease. Now, a new study shows obesity may also increase the chance of developing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 9, 2018 Category: General Medicine Source Type: news
Fewer Dialysis Patients Facing Leg Amputations
Patients with kidney disease have a higher risk for losing a leg because they have an increased risk for peripheral artery disease, which occurs when there's not enough blood reaching the legs. (Source: WebMD Health)
Source: WebMD Health - July 31, 2018 Category: Consumer Health News Source Type: news
Are Bioresorbable Stents Destined for a Comeback?
The excitement around bioresorbable stents might have calmed down considerably over the last year, but all that could change. Reva Medical, a San Diego, CA-based company is bringing the technology back into the spotlight with a recent approval. The company has received a CE mark for its Motiv bioresorbable scaffold to be used for the treatment of below-the-knee (BTK) peripheral artery disease (PAD).
The CE mark is also significant for Reva because it marks the company’s entry into the PAD space. The company already has CE mark for its Fantom bioresorbable scaffold, which treats patients for coronary arter...
Source: MDDI - July 31, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
Cardiovascular Systems shares steady on Q4, FY2018 earnings beat
Shares in Cardiovascular Systems (NSDQ:CSII) have stayed steady in after-hours trading after the medical device maker posted full year and fourth quarter fiscal year 2018 earnings that beat expectations on Wall Street.
The St. Paul, Minn.-based company posted profits of $3.7 million, or 11¢ per share, on sales of $59.2 million for the three months June 30, seeing massive 384.1% growth on the bottom-line while sales grew 11.8% compared with the same period during the previous year.
Earnings per share beat the 6¢ expectations on Wall Street, where analysts expected too see sales of $58.2 million, which the company also to...
Source: Mass Device - July 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Cardiovascular Systems Inc. Source Type: news
27.07.18: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery diseasePositive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic eventsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 27, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease (for specialized target groups only)
Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events (Source: Bayer Company News)
Source: Bayer Company News - July 27, 2018 Category: Pharmaceuticals Source Type: news
Reva wins CE Mark for bioresorbable scaffold in below-the-knee PAD
Reva Medical (ASX:RVA) said yesterday it won CE Mark approval in the European Union for its Motiv bioresorbable drug-eluting scaffold, now cleared for treatment of below-the-knee peripheral artery disease.
The San Diego-based company’s Motiv is made from the company’s proprietary radiopaque Tyrocore polymer designed for vascular scaffolds. Reva said that over the coming months, it will select centers to analyze the device’s performance for future user and other applications.
Read the whole story on our sister site, Drug Delivery Business News
The post Reva wins CE Mark for bioresorbable scaffold in below...
Source: Mass Device - July 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Drug-Device Combinations Drug-Eluting Stents Regulatory/Compliance Vascular Reva Medical Inc. Source Type: news
Ra Medical registers for $87m IPO
Ra Medical yesterday registered for an initial public offering worth up to $86.5 million, according to a recently posted SEC filing.
The Carlsbad, Calif.-based company said it plans to list on the New York Stock Exchange under the symbol “RMED,” according to the SEC posting.
Piper Jaffray and Cantor Fitzgerald are acting as joint book runners for the offering, according to the filing.
Ra Medical produces the Dabra atherectomy catheter laser designed to treat patients with peripheral artery disease. The system is designed to destroy arteriosclerotic blockages through the use of radiation ablation, which the com...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Ra Medical Source Type: news
Avenger receives FDA approval for Pantheris altherectomy device
Avinger (Redwood City, Calif.) recently received FDA approval for its Pantheris image-guided altherectomy device that is designed to treat peripheral artery disease (PAD).
Pantheris is the first medical device to be approved for diagnostics and treatment of PAD. The device lets doctors see inside arteries to treat blockages. It features a built-in camera and can shave plaque without causing damage to blood vessels.
The device can also be used by physicians to use the real-time intravascular imaging tool to identify features of blood vessels, include necrotic cores, fibroatheromas, calcium and stent struts.
Get the full sto...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Cardiovascular Avinger Source Type: news
